Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407499 | 0.93 | AGTR1 (0.61) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL12730813 | 0.90 | AGTR1 (0.57) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL3425230 | 0.89 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL5773556 | 0.88 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL8913861 | 0.87 | AGTR1 (0.52) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL14169520 | 0.87 | AGTR1 (0.53) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6755888 | 0.86 | AGTR1 (0.59) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL4814768 | 0.86 | AGTR1 (0.60) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL5774766 | 0.86 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Methyl Isobutyl Ketone SCHEMBL6755889 | 0.86 | AGTR2 (0.57) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891055-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM | Medichem, S.A. (ES) | 2008-02-27 | — | — | EP | claimed |
| WO-2007020533-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM | MEDICHEM, S.A. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-1019048-B1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME ITALIA S P A (IT) | 2004-01-21 | — | — | EP | disclosed |
| US-6576652-B2 | Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension. | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2003-06-10 | — | — | US | disclosed |
| EP-1294712-A1 | PROCESS FOR THE CRYSTALLIZATION OF LOSARTAN POTASSIUM | Aurobindo Pharma Limited (IN) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002094816-A1 | PROCESS FOR THE CRYSTALLIZATION OF LOSARTAN POTASSIUM | AUROBINDO PHARMA LIMITED (IN) | 2002-11-28 | — | — | WO | disclosed |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2002-08-22 | — | — | US | disclosed |
| EP-1019048-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | Merck Sharp Dohme (Italia) S.P.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999016437-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME (ITALIA) S.P.A. (IT) | 1999-04-08 | — | — | WO | disclosed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | disclosed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885ABCC4 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.